Athersys (ATHX) stock forecast for 2027
Last update: September 24, 2022 (07:30)Sector: Healthcare
The share price of Athersys, Inc. (ATHX) now
What analysts predict:: $3
52-week high/low: $36 / $1.13
50/200 Day Moving Average: $4.422 / $13.47
This figure corresponds to the average price over the previous 50/200 days. For Athersys stocks, the 50-day moving average is the resistance level today.
For Athersys stocks, the 200-day moving average is the resistance level today.
Are you interested in Athersys stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Athersys stock price in 2027. How much will one Athersys share be worth in 2027?
Is it worth taking profit / loss on Athersys stock now or waiting? What are analysts' forecasts for Athersys stock?
We forecast Athersys stock performance using neural networks based on historical data on Athersys stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Athersys stock prediction results are shown below and presented as a graph, table and text information.
Athersys stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Athersys analysts is $3.
Today 200 Day Moving Average is the resistance level (13.47 $).
50 Day Moving Average is the resistance level (4.422 $).
Historical and forecast chart of Athersys stock
The chart below shows the historical price of Athersys stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Athersys stock price can be found in the table below.
Athersys (ATHX) Forecast for 2027
Athersys information and performance
Athersys Inc. is an international biotech company focused primarily on the field of regenerative medicine. The Company’s Multistem Cell Therapy, an allogeneic stem cell product, is its flagship platform product and is in a later stage of clinical development. Its clinical development programs are focused on the treatment of neurological diseases, cardiovascular disease, inflammatory and immune disorders, certain lung diseases, and other conditions where the standard of care is limited or inadequate for many patients.
3201 CARNEGIE AVENUE, CLEVELAND, OH, US
Market Capitalization: 356 979 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -78 362 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: -0.34
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.431
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 0.859
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 43.64
Enterprise Value (EV) /Revenue
EV To EBITDA: -5.63
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 305110000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Athersys price target for 2021 by month
Target values for the price of one Athersys share for Jan 2027.
Pessimistic target level: 1.24
Optimistic target level: 1.63
Target values for the price of one Athersys share for Feb 2027.
Pessimistic target level: 1.13
Optimistic target level: 1.43
Target values for the price of one Athersys share for Mar 2027.
Pessimistic target level: 1.24
Optimistic target level: 1.49
Target values for the price of one Athersys share for Apr 2027.
Pessimistic target level: 1.06
Optimistic target level: 1.21
Target values for the price of one Athersys share for May 2027.
Pessimistic target level: 1.04
Optimistic target level: 1.26
Target values for the price of one Athersys share for Jun 2027.
Pessimistic target level: 1.27
Optimistic target level: 1.54
Target values for the price of one Athersys share for Jul 2027.
Pessimistic target level: 1.32
Optimistic target level: 1.79
Target values for the price of one Athersys share for Aug 2027.
Pessimistic target level: 1.34
Optimistic target level: 1.68
Target values for the price of one Athersys share for Sep 2027.
Pessimistic target level: 1.47
Optimistic target level: 1.81
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.